PI3K/Akt/mTOR

CAS号：162635-04-3

品名：西罗莫司脂化物Temsirolimus

中文别名：替西罗莫司;西罗莫司;

英文别名：CCL-779;Rapamycin(42-[3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate];[14C]-Temsirolimus;TeMsiroliMus(CCI-779,Torisel);TeMsiroliMus(~);rapaMycin42-esterwith3-hydroxy-2-(hydroxyMethyl)-2-Methylpropionicacid;42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]rapamycin;TeMsiroliMus(Torisel);Rapamycin42-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate;(1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate;

分子式：C56H87NO16

分子量：1030.29

精确质量：1029.6

Psa：241.96

UNII号：624KN6GM2T

密度：1.2g/cm3

沸点：1048.4ºC at 760mmHg

熔点：99-101ºC

闪点：587.8ºC

折射率：1.553

蒸汽压：0mmHg at 25°C

简介：Temsirolimus(CCI-779)isanintravenousdrugforthetreatmentofrenalcellcarcinoma(RCC),developedbyWyethPharmaceuticalsandapprovedbytheU.S.FoodandDrugAdministration(FDA)inlateMay2007,andwasalsoapprovedbytheEuropeanMedicinesAgency(EMEA)onNovember2007.ItisaderivativeandprodrugofsirolimusandissoldasTorisel.

PI3K/Akt/mTOR

CAS号：667463-62-9

品名：(2'Z,3'E)-6-溴靛玉红-3'-肟BIO,(2'Z,3'E)-6-Bromoindirubin-3'-oxime

中文别名：(2'Z,3'E)-6-溴靛玉红-3'-肟

英文别名：6-bromoindirubin-3'-oxime;6-bromoindirubin-3'-monoxime;

分子式：C16H10BrN3O2

分子量：356.174

精确质量：354.996

Psa：73.72

密度：1.8g/cm3

沸点：554.3ºC at 760 mmHg

闪点：289ºC

折射率：1.801

储存条件：2-8ºC

安全说明：S26; S36

危险类别码：R36/37/38

危险品标志：Xi